MedPath

Pharmacokinetics of Acetaminophen in Morbidly Obese Patients

Phase 4
Completed
Conditions
Morbid Obesity
Interventions
Registration Number
NCT01764555
Lead Sponsor
St. Antonius Hospital
Brief Summary

This study will investigate the pharmacokinetics of acetaminophen in morbidly obese patients versus normal weight patients. Specifically the different metabolic pathways of acetaminophen in morbidly obese adults will be investigated; glucuronidation, sulphation and CYP2E1 (cytochrome P450 2E1) oxidation

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
mobidly obese patientsacetaminophen 2 gmorbidly obese patients receiving acetaminophen 2 g instead of 1 g
normal weight patientsacetaminophen 2 gnormal weight patients receiving acetaminophen 2 g instead of 1 g
Primary Outcome Measures
NameTimeMethod
Volume of distribution of acetaminophen in morbidly obese patients in comparison with normal weight patients.24 hours
Clearance (total, glucuronidation, sulphation, CYP2E1 oxidation and unchanged) of acetaminophen in morbidly obese patients in comparison with normal weight patients.24 hours
Secondary Outcome Measures
NameTimeMethod
Difference in clearance (total, glucuronidation, sulphation, CYP2E1 oxidation) of acetaminophen in morbidly obese patients at the time of bariatric surgery and at 0.5 - 2 year after bariatric surgery.8 hours
Difference in volume of distribution of acetaminophen in morbidly obese patients at the time of bariatric surgery and at 0.5 - 2 year after bariatric surgery.8 hours
Liver function tests in morbidly obese patients in comparison with normal weight patients.24 hours

Trial Locations

Locations (1)

St. Antonius Hospital

🇳🇱

Nieuwegein, Netherlands

© Copyright 2025. All Rights Reserved by MedPath